CN104703604A - 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物 - Google Patents
作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物 Download PDFInfo
- Publication number
- CN104703604A CN104703604A CN201380038158.1A CN201380038158A CN104703604A CN 104703604 A CN104703604 A CN 104703604A CN 201380038158 A CN201380038158 A CN 201380038158A CN 104703604 A CN104703604 A CN 104703604A
- Authority
- CN
- China
- Prior art keywords
- compound
- acid
- alkyl
- disease
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZTRCHZUPKFKKOS-QINSGFPZSA-N CCCC/N=C(/c1nnc(N2CCN(C)CC2)[s]1)\SCC Chemical compound CCCC/N=C(/c1nnc(N2CCN(C)CC2)[s]1)\SCC ZTRCHZUPKFKKOS-QINSGFPZSA-N 0.000 description 1
- 0 CCCCN(N)N=C(C)[C@@](Cc1c[n]c2ccccc12)NC(C1=C*C(N2CCN(C)CC2)=S1)=O Chemical compound CCCCN(N)N=C(C)[C@@](Cc1c[n]c2ccccc12)NC(C1=C*C(N2CCN(C)CC2)=S1)=O 0.000 description 1
- RGYKOIKSNLAMIM-UHFFFAOYSA-N CCCc1nnc(C(Cc2c[nH]c3ccccc23)NC(c2cnc(N3CCN(C)CC3)[s]2)=O)[s]1 Chemical compound CCCc1nnc(C(Cc2c[nH]c3ccccc23)NC(c2cnc(N3CCN(C)CC3)[s]2)=O)[s]1 RGYKOIKSNLAMIM-UHFFFAOYSA-N 0.000 description 1
- ROAWUMWPZUJDOD-UHFFFAOYSA-N CCc1c[s]c(C(Cc2c[nH]c3ccccc23)NC(c2cnc(N3CCN(C)CC3)[s]2)=O)n1 Chemical compound CCc1c[s]c(C(Cc2c[nH]c3ccccc23)NC(c2cnc(N3CCN(C)CC3)[s]2)=O)n1 ROAWUMWPZUJDOD-UHFFFAOYSA-N 0.000 description 1
- VLUNZVPCLFFDRH-UHFFFAOYSA-N CN(CC1)CCN1c1nnc(C=O)[s]1 Chemical compound CN(CC1)CCN1c1nnc(C=O)[s]1 VLUNZVPCLFFDRH-UHFFFAOYSA-N 0.000 description 1
- QYHMWDMWFRSEOE-UHFFFAOYSA-N CN(CC1)CCN1c1nnc(CO)[s]1 Chemical compound CN(CC1)CCN1c1nnc(CO)[s]1 QYHMWDMWFRSEOE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672239P | 2012-07-16 | 2012-07-16 | |
| US61/672,239 | 2012-07-16 | ||
| PCT/US2013/050719 WO2014014937A1 (en) | 2012-07-16 | 2013-07-16 | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104703604A true CN104703604A (zh) | 2015-06-10 |
Family
ID=49949212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380038158.1A Pending CN104703604A (zh) | 2012-07-16 | 2013-07-16 | 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9284309B2 (enExample) |
| EP (1) | EP2872143B1 (enExample) |
| JP (1) | JP2015522617A (enExample) |
| KR (1) | KR20150031481A (enExample) |
| CN (1) | CN104703604A (enExample) |
| AU (1) | AU2013290361A1 (enExample) |
| BR (1) | BR112015001096A2 (enExample) |
| CA (1) | CA2877983A1 (enExample) |
| ES (1) | ES2661394T3 (enExample) |
| HK (1) | HK1210598A1 (enExample) |
| IL (1) | IL236712A0 (enExample) |
| IN (1) | IN2015DN01171A (enExample) |
| MX (1) | MX2015000618A (enExample) |
| RU (1) | RU2015104962A (enExample) |
| WO (1) | WO2014014937A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110191885A (zh) * | 2017-01-26 | 2019-08-30 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物 |
| CN110198938A (zh) * | 2017-01-26 | 2019-09-03 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的双-杂芳基衍生物 |
| CN113683598A (zh) * | 2020-05-18 | 2021-11-23 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2025223458A1 (zh) * | 2024-04-23 | 2025-10-30 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ722487A (en) | 2014-01-29 | 2022-04-29 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
| EP3328379B1 (en) | 2015-07-29 | 2021-07-28 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| JP7073385B2 (ja) | 2017-01-26 | 2022-05-23 | ユーシービー バイオファルマ エスアールエル | タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体 |
| US20190382346A1 (en) | 2017-02-28 | 2019-12-19 | Universitat Autonoma De Barcelona | (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies |
| WO2019025424A1 (en) | 2017-08-04 | 2019-02-07 | Universitat Autonoma De Barcelona | COMPOUNDS FOR TREATING SYNUCLEINOPATHIES |
| WO2019161917A1 (en) | 2018-02-23 | 2019-08-29 | Universitat Autonoma De Barcelona | 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| WO2011084642A1 (en) * | 2009-12-16 | 2011-07-14 | Neuropore Therapies, Inc. | Compound suitable for the treatment of synucleopathies |
| US20120083475A1 (en) * | 2009-06-11 | 2012-04-05 | Gerard Griffioen | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU782878B2 (en) | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| JP4052573B2 (ja) | 2000-09-15 | 2008-02-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用 |
| AU2010243613B2 (en) * | 2009-04-30 | 2015-05-07 | Glaxo Group Limited | Oxazole substituted indazoles as PI3-kinase inhibitors |
| US9198891B2 (en) | 2010-05-21 | 2015-12-01 | New York University | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase |
-
2013
- 2013-07-16 JP JP2015523185A patent/JP2015522617A/ja active Pending
- 2013-07-16 CN CN201380038158.1A patent/CN104703604A/zh active Pending
- 2013-07-16 AU AU2013290361A patent/AU2013290361A1/en not_active Abandoned
- 2013-07-16 KR KR20157004215A patent/KR20150031481A/ko not_active Withdrawn
- 2013-07-16 BR BR112015001096A patent/BR112015001096A2/pt not_active Application Discontinuation
- 2013-07-16 HK HK15111382.6A patent/HK1210598A1/xx unknown
- 2013-07-16 US US14/415,120 patent/US9284309B2/en active Active
- 2013-07-16 MX MX2015000618A patent/MX2015000618A/es unknown
- 2013-07-16 ES ES13820320.3T patent/ES2661394T3/es active Active
- 2013-07-16 CA CA2877983A patent/CA2877983A1/en not_active Abandoned
- 2013-07-16 EP EP13820320.3A patent/EP2872143B1/en active Active
- 2013-07-16 WO PCT/US2013/050719 patent/WO2014014937A1/en not_active Ceased
- 2013-07-16 RU RU2015104962A patent/RU2015104962A/ru not_active Application Discontinuation
-
2015
- 2015-01-14 IL IL236712A patent/IL236712A0/en unknown
- 2015-02-12 IN IN1171DEN2015 patent/IN2015DN01171A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| US20120083475A1 (en) * | 2009-06-11 | 2012-04-05 | Gerard Griffioen | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases |
| WO2011084642A1 (en) * | 2009-12-16 | 2011-07-14 | Neuropore Therapies, Inc. | Compound suitable for the treatment of synucleopathies |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110191885A (zh) * | 2017-01-26 | 2019-08-30 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物 |
| CN110198938A (zh) * | 2017-01-26 | 2019-09-03 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的双-杂芳基衍生物 |
| CN110198938B (zh) * | 2017-01-26 | 2023-03-14 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的双-杂芳基衍生物 |
| CN110191885B (zh) * | 2017-01-26 | 2023-05-16 | Ucb生物制药私人有限公司 | 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物 |
| CN113683598A (zh) * | 2020-05-18 | 2021-11-23 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| CN113683598B (zh) * | 2020-05-18 | 2022-10-14 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2025223458A1 (zh) * | 2024-04-23 | 2025-10-30 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL236712A0 (en) | 2015-02-26 |
| EP2872143A4 (en) | 2015-12-02 |
| HK1210598A1 (en) | 2016-04-29 |
| EP2872143A1 (en) | 2015-05-20 |
| ES2661394T3 (es) | 2018-03-28 |
| EP2872143B1 (en) | 2017-12-13 |
| BR112015001096A2 (pt) | 2017-06-27 |
| US20150183776A1 (en) | 2015-07-02 |
| AU2013290361A1 (en) | 2015-02-05 |
| JP2015522617A (ja) | 2015-08-06 |
| US9284309B2 (en) | 2016-03-15 |
| WO2014014937A1 (en) | 2014-01-23 |
| MX2015000618A (es) | 2015-04-10 |
| KR20150031481A (ko) | 2015-03-24 |
| IN2015DN01171A (enExample) | 2015-06-26 |
| CA2877983A1 (en) | 2014-01-23 |
| RU2015104962A (ru) | 2016-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104703604A (zh) | 作为蛋白质聚集抑制剂的二-和三-杂芳基衍生物 | |
| ES2724275T3 (es) | 1,2,4-triazoles como moduladores del transporte nuclear y usos de los mismos | |
| KR102383038B1 (ko) | 단백질 응집 저해제로서의 헤테로아릴 아미드 | |
| JP6926189B2 (ja) | エストロゲン受容体調節薬 | |
| ES2950450T3 (es) | Análogos de piridazina con disustitución 1,4 y métodos para tratar afecciones relacionadas con la deficiencia de SMN | |
| DK2380881T3 (en) | NEW BICYCLIC HETEROCYCLIC COMPOUND | |
| ES2654617T3 (es) | Inhibidores de PDE10 y composiciones y procedimientos relacionados | |
| ES2988059T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
| BR112015032921B1 (pt) | Compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos | |
| JPWO2007102531A1 (ja) | 併用薬 | |
| JP2024041888A (ja) | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 | |
| JP2021522201A (ja) | Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール系化合物 | |
| KR20220130697A (ko) | 새로운 화합물 및 그 용도 | |
| EP3397634A1 (en) | Nuclear transport modulators and uses thereof | |
| ES2861317T3 (es) | Moduladores de SOCE, composiciones y usos de los mismos | |
| JP6159388B2 (ja) | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 | |
| CA2976972A1 (en) | 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathway | |
| ES3011633T3 (en) | Thiophene compounds, process for synthesis and use thereof for the treatment of autoimmune disorders | |
| JP2023532996A (ja) | Ｆａｂｐ４調節化合物の抗ウイルス的使用 | |
| CN115785094B (zh) | 苄基取代α-咔啉化合物或其药用盐、其药物组合物及其制备方法和用途 | |
| ES2701975A2 (es) | Uso de ligandos del receptor sigma en el dolor post-herpetico | |
| CN103958501B (zh) | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 | |
| EA040280B1 (ru) | КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ СТИМУЛЯТОРЫ sGC | |
| OA18506A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
| NZ612990B2 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150610 |